MD
Pediatrix Medical Group, Inc.22.32
-0.37-1.63%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reaffirms flat 2026 guidance
Q&A largely reaffirmed the prepared outlook, clarifying 2026 revenue holds flat on steady volumes and pricing despite Q4's tough comps dragging volumes 3% lower. Management stressed no payer mix shifts yet from ACA subsidy risks--too many variables to quantify--with early 2026 signals steady. Smaller buybacks are assumed versus 2025's $64 million deploy, while opportunistic M&A garners inbound interest in tuck-ins and OB hospitalists without straying from core. Pricing drivers like acuity and RCM collections should moderate. No surprises. Watch ACA impacts and growth execution.
Key Stats
Market Cap
1.94BP/E (TTM)
11.69Basic EPS (TTM)
1.91Dividend Yield
0%Recent Filings
8-K
Q4 revenue dips, profits soar
Pediatrix reported Q4 net revenue of $494M, down from $502M prior year due to practice dispositions but buoyed by 4.0% same-unit growth from better reimbursements and acuity. Net income hit $34M or $0.40/share, with Adjusted EBITDA at $66M; full-year swung to $165M profit from 2024's $99M loss. Guides 2026 Adjusted EBITDA to $280M-$300M. Cash swelled to $375M.
10-K
FY2025 results
Pediatrix posted FY2025 net revenue of $1.91B, down 4.9% y/y from practice exits, yet same-unit revenue accelerated 6.2% on 5.7% reimbursement gains from acuity, payor mix, and collections, plus 0.5% volume lift in neonatology and maternal-fetal. Q4 momentum shone through hospital admin fees at 14% of revenue and operating margin hitting 10.9%, up from (3.4)% amid restructuring. Cash flow surged to $275M; $596M debt steady with $450M revolver dry. Repurchased $87M shares. Medicaid reforms threaten reimbursement flows.
8-K
Q3 beat, EBITDA raised
Pediatrix beat Q3 expectations with $493M revenue, $72M net income, and $87M Adjusted EBITDA—up from $60M last year—fueled by 8.0% same-unit revenue growth from collections, acuity, and payor mix. Revenue dipped overall due to practice dispositions. Raised full-year Adjusted EBITDA outlook to $270M-$290M. Cash flow soared.
10-Q
Q3 FY2025 results
Pediatrix posted Q3 revenue of $492.9M, down 3.6% y/y from $511.2M yet swinging to $68.1M operating income from $33.8M, while YTD revenue fell 6.0% y/y to $1.42B but operating income soared to $160.0M from a $108.0M loss (derived). Same-unit revenue climbed 8.0% y/y on better collections, acuity, and volumes, trimming practice salaries 8.9% y/y; diluted EPS hit $0.84 from $0.23, reconciling to 85.6M shares. Cash swelled to $340.1M with $156.9M operating cash flow; total debt $602.5M (Term A Loan $201.6M at SOFR+margin maturing 2027, $400M 5.375% 2030 Notes) and $450M revolver available. Closed Sep 2025 acquisition for $19.2M cash, recording $12.8M goodwill and $6.1M intangibles. Strong cash builds firepower. Litigation risk looms large.
8-K
$250M buyback authorized
Pediatrix Medical Group announced a $250 million share repurchase program on August 18, 2025, authorized by its Board for a three-year term. Backed by strong cash flow and low debt, repurchases will occur opportunistically via open market or private deals, balanced against business growth investments. No shares obligated. Execution hinges on market conditions.
IPO
Website
Employees
Sector
Industry
ARDT
Ardent Health, Inc.
8.93+0.03
BMGL
Basel Medical Group Ltd
0.76-0.10
CON
Concentra Group Holdings Parent
19.55-0.33
HCA
HCA Healthcare, Inc.
469.79-7.19
INNV
InnovAge Holding Corp.
5.55-0.27
NUTX
Nutex Health Inc.
171.72-4.06
PACS
PACS Group, Inc.
34.20-0.55
PAIYY
Aesthetic Medical International
0.13+0.00
PIII
P3 Health Partners Inc.
4.59-0.36
PNTG
The Pennant Group, Inc.
29.73+0.00